Literature DB >> 41549

The effect of spontaneous changes in urinary pH on mexiletine plasma concentrations and excretion during chronic administration to healthy volunteers.

A Johnston, C D Burgess, S J Warrington, J Wadsworth, N A Hamer.   

Abstract

1. The effect of spontaneous changes in urinary pH on renal excretion and plasma concentration of mexiletine has been examined during chronic administration of subtherapeutic doses of the drug to healthy volunteers. 2. Significant correlations were found between urinary pH and the plasma concentration and renal excretion of mexiletine. 3. Prediction of plasma mexiletine concentrations from our data suggests that the amount of mexiletine in plasma would increase by more than 50% following a rise in urinary pH similar to that which occurred spontaneously in our subjects. 4. Factors which influence urinary pH should be considered when the dosage of mexiletine is chosen. Extremes of urinary pH may account for some cases of inefficacy of the drug, and for the occurrence of unwanted effects at conventional doses.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 41549      PMCID: PMC1429840          DOI: 10.1111/j.1365-2125.1979.tb04717.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  1 in total

1.  The clinical pharmacology of mexiletine.

Authors:  N P Campbell; J G Kelly; A A Adgey; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

  1 in total
  9 in total

Review 1.  Is there an ideal antiarrhythmic drug? A review--with particular reference to class I antiarrhythmic agents.

Authors:  K A Muhiddin; P Turner
Journal:  Postgrad Med J       Date:  1985-08       Impact factor: 2.401

Review 2.  Clinical pharmacokinetics of mexiletine.

Authors:  L Labbé; J Turgeon
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

3.  The influence of urinary pH on flecainide excretion and its serum pharmacokinetics.

Authors:  K A Muhiddin; A Johnston; P Turner
Journal:  Br J Clin Pharmacol       Date:  1984-04       Impact factor: 4.335

4.  Enhanced metabolism of mexiletine after phenytoin administration.

Authors:  E J Begg; P M Chinwah; C Webb; R O Day; D N Wade
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

Review 5.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

6.  The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.

Authors:  F Broly; N Vandamme; C Libersa; M Lhermitte
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

7.  Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine.

Authors:  P Lledó; S M Abrams; A Johnston; M Patel; R M Pearson; P Turner
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

8.  Mexiletine disposition: individual variation in response to urine acidification and alkalinisation.

Authors:  B G Mitchell; J A Clements; A Pottage; L F Prescott
Journal:  Br J Clin Pharmacol       Date:  1983-09       Impact factor: 4.335

9.  Pharmacokinetics of mexiletine in renal insufficiency.

Authors:  D El Allaf; L Henrard; L Crochelet; D Delapierre; J Carlier; A Dresse
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.